Search
Close this search box.

A Novel Beads-free CAR T-Cell Manufacturing Platform

Chimeric antigen receptors (CARs) T-cell therapy has become an important approach for cancer treatment. This project aims develop a novel perfusion-based, beads-free, bioreactor system as a new platform for CAR T cell manufacturing with the intent to simp
Categories
Cell and Gene therapies
Project status
100% Completed

Solution

Performance Period: 4/1/2021 to 5/31/2023

Chimeric antigen receptors (CARs) T-cell therapy has become an important approach for cancer treatment. This project aims develop a novel perfusion-based, beads-free, bioreactor system as a new platform for CAR T cell manufacturing with the intent to simplify the manufacturing process and form the foundation for achieving full automation. The system is designed to facilitate scaling the manufacturing of CAR T cells for different uses, which can then be applied across a broad array of T-cell based applications. The approach aims to reduce development costs, shorten timelines, and bring direct benefit to patients. 

Outcomes and Impacts

The development of this novel perfusion-based system would facilitate scaling the manufacturing of CAR T cells for different users.

Updates, Related Publications, and Deliverables

  • Login to the NIIMBL member portal for access to project updates, related publications, and deliverables. 

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

Southwest Research Institute

Southwest Research Institute

Participating Organizations

Genentech

Genentech

Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC

University of Pennsylvania

University of Pennsylvania

Xcellerate Biotech Inc.

Xcellerate Biotech Inc.

Join Our Mailing List

MailChimp NIIMBL Mailing List Signup
Organization Type
How did you first hear about NIIMBL?